Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment

Journal of Infectious Diseases

Volumn 202, Issue 10, 2010, Pages 1538-1542

  Graham, Susan M ^a,c,e,g   Masese, Linnet ^a,c   Gitau, Ruth ^c   Jalalian Lechak, Zahra ^b   Richardson, Barbra A ^a   Peshu, Norbert ^e   Mandaliya, Kishor ^f   Kiarie, James N ^d   Jaoko, Walter ^c   Ndinya Achola, Jeckoniah ^c   Overbaugh, Julie ^b   McClelland, R Scott ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d KENYATTA NATIONAL HOSPITAL   (Kenya)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f Department of Obstetrics and Gynaecology   (Kenya)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEMALE GENITAL SYSTEM; GENOTYPE; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; NEUROPATHY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VAGINA; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS SHEDDING; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CERVIX UTERI; DISEASE TRANSMISSION, INFECTIOUS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; LAMIVUDINE; NEVIRAPINE; PATIENT COMPLIANCE; RISK FACTORS; RNA, VIRAL; STAVUDINE; VAGINA; VIRUS SHEDDING;

EID: 78349288892     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656790     Document Type: Article

References (15)

1. Joint United Nations Programme on HIV/AIDS. 2008 Report on the global AIDS epidemic. Geneva: UNAIDS, 2008.
2. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421.
3. Graham SM, Holte SE, Peshu NM, et al. Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007; 21:501-507.
4. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
5. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
6. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358:1593-1601.
7. De Pasquale MP, Leigh Brown AJ, Uvin SC, et al. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34:37-44.
8. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009; 301:2380-2382.
9. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 1997; 350:922-927.
10. Kenya Ministry of Health. Guidelines to antiretroviral drug therapy in Kenya. Nairobi: Kenya Ministry of Health, 2005.
11. John GC, Sheppard H, Mbori-Ngacha D, et al. Comparison of techniques for HIV-1 RNA detection and quantitation in cervicovaginal secretions. J Acquir Immune Defic Syndr 2001; 26:170-175.
12. DeVange Panteleeff D, Emery S, Richardson BA, et al. Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples. J Clin Microbiol 2002; 40:3929-3937.
13. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr 2009; 51:522-529.
14. Kwara A, DeLong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46:719-725.
15. Baeten J, Kahle E, Lingappa J, et al. Genital HIV-1 RNA concentrations and heterosexual HIV-1 transmission risk (abstract LBPEA07). Paper presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; 19-22 July 2009; Cape Town, South Africa. http://www.ias2009.org/ pag/Abstracts.aspx?AID=3770. Accessed 13 December 2009.